NCT05255666
Breast Cancer Type: Triple Negative
Hormone Mutations:
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Not yet recruiting
Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have at least one lesion greater than or equal to 5 mm in at least one dimension
Exclusions: Patients who have received prior liposomal irinotecan or irinotecan
https://ClinicalTrials.gov/show/NCT05255666